Press Releases

WATS3D Markedly Improves Detection of Esophageal Dysplasia and Barrett’s Esophagus in 12,899 Patient Study in the “Real World” Practice setting of 58 Community-Based Gastroenterologists

SUFFERN, NY, UNITED STATES - Dec 20, 2018 - SUFFERN, N.Y., Dec. 20, 2018 (GLOBE NEWSWIRE) -- CDx Diagnostics today announced the publication of new data demonstrating that the addition of WATS3D (Wide Area Transepithelial Sampling with 3D Tissue Analysis) to standard targeted and random forceps biopsy (FB) markedly increases the overall detection of esophageal dysplasia (ED) by 242% and the overall detection of Barretts esophagus (BE) by 153% in patients undergoing BE screening and surveillance
Dec 20, 2018
Certara Publishes New Report Investigating Success Factors for Outcomes-based Contracting, Giving Guidelines to Pharma and Payers

PRINCETON, NJ - Dec 19, 2018 - Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access, today announced a new research report that investigates the potential of pharmaceutical outcomes-based contracting
Dec 19, 2018
SINGULEX RECEIVES NEW, BROAD PATENT FOR HIGHLY SENSITIVE METHODS FOR ANALYSIS OF TROPONIN

ALAMEDA, CA, UNITED STATES OF AMERICA - Dec 17, 2018 - Contact: Marcia Ruggio
Global Brand Marketing Manager
m.ruggio@singulex.com
(510) 995-3859Singulex, Inc
Dec 17, 2018
QuantuMDx Group Limited and Molbio Diagnostics announce a Memorandum of Understanding

, UK & INDIA - Dec 12, 2018 - QuantuMDx Group Limited and Molbio Diagnostics Private Limited have signed a memorandum of understanding (MoU) to explore opportunities for joint working in infectious disease diagnostics, with an initial focus on genotypic drug resistance testing for those infected with tuberculosis
Dec 12, 2018
AusDiagnostics has CE marked a new kit for detection of haemochromatosis

SYDNEY, AUSTRALIA - Dec 10, 2018 - AusDiagnostics has CE marked a new kit for detection of haemochromatosis - a genetic disease that results in iron overload and eventually organ failure
Dec 9, 2018
New Clinical Data Further Validate SAVI SCOUT® Radar Localization System for Simpler, Positive Axillary Lymph Node Localization

SAN ANTONIO, TX, UNITED STATES - Dec 7, 2018 - SAN ANTONIO, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Data presented this week on wire-free radar breast localization demonstrated it may be a practical approach for positive axillary lymph node localization prior to neoadjuvant chemotherapy treatment (NAT) response
Dec 7, 2018
Certara Launches BaseCase Toolkits to Facilitate Pharmaceutical and Medical Device Field Teams’ HCP and Payer Presentations

PRINCETON, NJ - Dec 5, 2018 - Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access, today announced the launch of its BaseCase Toolkits, an add-on to BaseCase Interactive which helps pharmaceutical and medical device field representatives better manage and utilize their resources for use during customer presentations
Dec 5, 2018
At AES 2018 Cognizance Biomarkers Unveils Data Showing It Can Accurately Distinguish between Epileptic and Psychogenic Nonepileptic Seizures

SPRING HOUSE, PA, UNITED STATES - Dec 3, 2018 - Cognizance Biomarkers, LLC, a wholly-owned subsidiary of Evogen, Inc., a leader in proteomic and genomic-based testing for improved diagnosis and treatment of neurological disorders, today reported that a study1 being presented at the 2018 Annual Meeting of the American Epilepsy Society (AES) shows its blood-based neuroinflammatory biomarker test and algorithm can accurately distinguish epileptic seizures (ES) from psychogenic nonepileptic seizures (PNES)
Dec 2, 2018
Certara Launches Trial Simulator 2.3 to Improve Clinical Trial Success

PRINCETON, NJ - Nov 28, 2018 - Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access, today announced the launch of version 2
Nov 28, 2018
Check4Cancer launches innovative prostate cancer diagnosis pathway with AXA PPP healthcare

CAMBRIDGE, UK - Nov 27, 2018 - Prostate cancer is the most common cancer in men, with 1 in 8 diagnosed at some point in their lives
Nov 27, 2018
VIB Accelerates Therapeutic Biologics Discovery with Geneious Biologics

AUCKLAND CITY, NEW ZEALAND - Nov 15, 2018 - VIB Accelerates Therapeutic Biologics Discovery with Geneious Biologics

AUCKLAND, NZ - November 12, 2018 - Geneious Biologics, an enterprise software solution for companies engaged in screening of antibodies and antibody-like molecules, has been chosen by the VIB (a Life Sciences Research Institute in Belgium) to support therapeutic biologics discovery at its Discovery Sciences group
Nov 15, 2018
CareDx Announces Pricing of Public Offering of Common Stock

BRISBANE, CA - Nov 14, 2018 - CareDx Announces Pricing of Public Offering of Common StockBRISBANE, Calif., Nov. 13, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc
Nov 14, 2018
US FDA Awards Certara’s Simcyp Division Two New Dermal Virtual Bioequivalence Grants

PRINCETON, NJ - Nov 14, 2018 - Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access, today announced that it has been awarded two new dermal virtual bioequivalence grants by the US Food and Drug Administration (FDA)
Nov 14, 2018
MR Solutions shows new state-of-the-art bench top CT preclinical scanner with clip on PET and SPECT at nuclear medicine congress

GUILDFORD, UNITED KINGDOM - Nov 9, 2018 - MR Solutions continues to expand its range of preclinical scanners with the first showing of its elegant bench top CT scanner
Nov 9, 2018
Certara’s Evidence, Value & Access Specialists to Host Symposium on Automation in Public Health Decision-making and Present 18 Posters at ISPOR Europe

PRINCETON, NJ - Nov 8, 2018 - Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access, today announced that its Evidence, Value & Access team will host an educational symposium and present 18 research posters at ISPOR Europe 2018
Nov 8, 2018
International Biomedical Research Alliance Appoints J&J Development Corporation President to its Board of Directors

BETHESDA, MD - Nov 6, 2018 - The International Biomedical Research Alliance, a non-profit organization which provides programming and funding support for the National Institutes of Health (NIH) Oxford-Cambridge Scholars Program, today announced that Tom Heyman is joining the Alliances board of directors
Nov 6, 2018
Wision AI Applies Expertise in Machine-Learning and Mathematical Medicine to Improve Polyp Detection

LOS ANGELES, CA, UNITED STATES - Nov 5, 2018 - SHANGHAI, China, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Shanghai Wision AI
Co., Ltd, a leader in developing computer-aided diagnostic algorithms
and systems to improve the accuracy and effectiveness of diagnostic
imaging, today announced results of a study validating a novel
machine-learning algorithm that improves detection of adenomatous
polyps during colonoscopy
Nov 5, 2018
BioIVT Acquires Biological Specialty Corporation, Adds Donor Centers and Increases Its Immune Cell Capacity

WESTBURY, NY - Nov 5, 2018 - BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has acquired Biological Specialty Corporation (BSC), a supplier of human blood products and components to the life sciences research community for more than 37 years
Nov 5, 2018
Certara Scientists to Demonstrate Latest Modeling and Simulation Advances at AAPS PharmSci 360

PRINCETON, NJ - Nov 1, 2018 - Certara®, the global leader in model-informed drug development, regulatory science, market access and real-world evidence solutions, today announced that its scientists will lead 15 sessions, and also host a Phoenix User Group Meeting, at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting – PharmSci 360
Nov 1, 2018
Cofactor Genomics Launches ImmunoPrismTM Immune Profiling Kit, for Use in Clinical Sequencing Laboratories

SAN FRANCISCO, CA - Oct 30, 2018 - Cofactor Genomics Launches ImmunoPrismTM Immune Profiling Kit, for Use in Clinical Sequencing Laboratories --Enables in-house, RNA-based, solid tumor profiling with powerful, cloud-based informatics tools to inform critical clinical decisions-- Cofactor Genomics, a clinical RNA sequencing and translational assay developer, announced today the launch of a RNA-based immune profiling kit developed for laboratories wishing to derive the immune composition of tumor samples
Oct 30, 2018